Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells As a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease

Overview

Journal Dig Dis

Specialty Gastroenterology

Date 2020 Aug 8

PMID 32759604

Citations 3

Authors

Naohisa Wada

Haruki Uojima

Takashi Satoh

Sosei Okina

Shuichiro Iwasaki

Xue Shao

Hayato Takiguchi

Yoshitaka Arase

Norio Itokawa

Masanori Atsukawa

Koji Miyazaki

Hisashi Hidaka

Makoto Kako

Tatehiro Kagawa

Katsuhiko Iwakiri

Ryouichi Horie

Takahiro Suzuki

Wasaburo Koizumi

Affiliations

Soon will be listed here.

Abstract

Background: To make an accurate estimate of the response to thrombopoietin (TPO) receptor agonists for thrombocytopenia associated with chronic liver disease, we evaluated the influence of antiplatelet autoantibodies on the response to lusutrombopag in thrombocytopenic patients with liver disease.

Methods: A prospective study was conducted at 2 hospitals. Thrombocytopenic patients with liver disease received oral lusutrombopag 3.0 mg once daily for up to 7 days. We analyzed changes in platelet counts from baseline to the maximum platelet count on days 9-14. The definition of clinical response was a platelet count of ≥5 × 104/μL with an increased platelet count of ≥2 × 104/μL from baseline. We assessed the correlation between the response to treatment drug and antiplatelet autoantibodies measured by anti-GPIIb/IIIa antibody-producing B cells.

Results: Thirty patients received the trial drug. There were 25 responders and 5 nonresponders. The median change in platelet counts was 3.9 × 104/μL (95% CI 2.8-4.6, p < 0.0001). The correlation between change in platelet counts and the frequency of the anti-glycoprotein IIb/IIIa antibody-producing B cells was moderate (r = 0.414, 95% CI 0.064-0.674, p = 0.023). In multivariate analysis of factors affecting the change in platelet counts, the anti-GPIIb/IIIa antibody-producing B cells were identified as an independent factor (regression coefficient [B] = 0.089; CI 0.021-0.157, p = 0.013).

Conclusion: Anti-GPIIb/IIIa antibody-producing B cells may be a predictor for TPO receptor agonists in patients with chronic liver disease.

Citing Articles

Hepatitis of an Unknown Etiology with Concomitant ITP.

Tagliaferri A, Kania B, Patel D, Baig I, Farokhian A, Bellardini A J Community Hosp Intern Med Perspect. 2023; 13(1):67-71.

PMID: 36817307 PMC: 9924622. DOI: 10.55729/2000-9666.1150.

Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study.

Ding J, Feng T, Sun W, Cai X, Zhang Y, Zhao W World J Gastrointest Surg. 2022; 14(11):1260-1271.

PMID: 36504518 PMC: 9727570. DOI: 10.4240/wjgs.v14.i11.1260.

B cell-activating factor is involved in thrombocytopenia in patients with liver cirrhosis.

Satoh T, Takiguchi H, Uojima H, Kubo M, Tanaka C, Yokoyama F Ann Hematol. 2022; 101(11):2433-2444.

PMID: 36098792 DOI: 10.1007/s00277-022-04973-x.

References

Wang L, Gao Z, Chen X, Zhang H, Yang N, Wang F . Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis. Sci Rep. 2016; 6:39003. PMC: 5171907. DOI: 10.1038/srep39003. View

Mitchell O, Feldman D, Diakow M, Sigal S . The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016; 8:39-50. PMC: 4847598. DOI: 10.2147/HMER.S74612. View

Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K . Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018; 24(46):5271-5279. PMC: 6295839. DOI: 10.3748/wjg.v24.i46.5271. View

Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P, Mezzano D . Platelet autoantibodies in patients with chronic liver disease. Am J Hematol. 1995; 50(3):173-8. DOI: 10.1002/ajh.2830500305. View

Kuwana M, Okazaki Y, Satoh T, Asahi A, Kajihara M, Ikeda Y . Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. Am J Med. 2005; 118(9):1026-33. DOI: 10.1016/j.amjmed.2004.12.027. View

Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel J . Thrombopoietin receptor agonists: ten years later. Haematologica. 2019; 104(6):1112-1123. PMC: 6545830. DOI: 10.3324/haematol.2018.212845. View

Hitchcock I, Kaushansky K . Thrombopoietin from beginning to end. Br J Haematol. 2014; 165(2):259-68. DOI: 10.1111/bjh.12772. View

Grotzinger K, Younossi Z, Giannini E, Chen P, Rendas-Baum R, Theodore D . Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies. Health Qual Life Outcomes. 2016; 14:49. PMC: 4802726. DOI: 10.1186/s12955-016-0447-1. View

Gonzalez-Porras J, Godeau B, Carpenedo M . Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019; 10:2040620719837906. PMC: 6515841. DOI: 10.1177/2040620719837906. View

10.

Cooper K, Fitzgerald P, Dillingham K, Helme K, Akehurst R . Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison. Int J Technol Assess Health Care. 2012; 28(3):249-58. DOI: 10.1017/S0266462312000414. View

11.

Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T . Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by multi-center prospective study. J Thromb Haemost. 2006; 4(9):1936-43. DOI: 10.1111/j.1538-7836.2006.02091.x. View

12.

Vainchenker W, Raslova H . Megakaryocyte polyploidization: role in platelet production. Platelets. 2019; 31(6):707-716. DOI: 10.1080/09537104.2019.1667497. View

13.

Cooper N, Ghanima W . Immune Thrombocytopenia. N Engl J Med. 2019; 381(10):945-955. DOI: 10.1056/NEJMcp1810479. View

14.

Wong R, Saleh M, Khelif A, Salama A, Portella M, Burgess P . Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood. 2017; 130(23):2527-2536. DOI: 10.1182/blood-2017-04-748707. View

15.

Elgebaly A, El Ashal G, Elfil M, Menshawy A . Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia: Meta-Analysis of Randomized Controlled Trials. Clin Appl Thromb Hemost. 2016; 23(8):928-937. DOI: 10.1177/1076029616663849. View

16.

Gangireddy V, Kanneganti P, Sridhar S, Talla S, Coleman T . Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014; 28(10):558-64. PMC: 4234356. DOI: 10.1155/2014/532191. View

17.

Hidaka H, Kurosaki M, Tanaka H, Kudo M, Abiru S, Igura T . Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. Clin Gastroenterol Hepatol. 2018; 17(6):1192-1200. DOI: 10.1016/j.cgh.2018.11.047. View

18.

Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M . Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res. 2019; 49(10):1169-1181. PMC: 6899664. DOI: 10.1111/hepr.13392. View

19.

Nilles K, Caldwell S, Flamm S . Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists. Hepatol Commun. 2019; 3(11):1423-1434. PMC: 6824078. DOI: 10.1002/hep4.1423. View

20.

Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y . A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology. 2003; 37(6):1267-76. DOI: 10.1053/jhep.2003.50209. View